ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups

por Quinn, D.I., Ng, C.F., Grande, E., Kwon, T.G., Linke, R., Lee, J.-L., Rosbrook, B., Thakur, M.N., Eto, M., Gross-Goupil, M.
Publicado 2021

Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

por Tomita, Y., Larkin, J., Venugopal, B., Haanen, J., Kanayama, H., Eto, M., Grimm, M.-O., Fujii, Y., Umeyama, Y., Huang, B., Mariani, M., di Pietro, A., Choueiri, T.K.
Publicado 2022

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

por Gross-Goupil, M, Kwon, T G, Eto, M, Ye, D, Miyake, H, Seo, S I, Byun, S -S, Lee, J L, Master, V, Jin, J, DeBenedetto, R, Linke, R, Casey, M, Rosbrook, B, Lechuga, M, Valota, O, Grande, E, Quinn, D I
Publicado 2018